Cyteir Therapeutics (CYT) Form 4 Cyteir Therapeutics / Luc Verelst ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Droia Invest II SCSp

(Last) (First) (Middle)

28 BOULEVARD JOSEPH II

(Street)

LUXEMBOURG N4 L-1840

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cyteir Therapeutics, Inc. [ CYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2021		C		3,259,026	A	(1)	3,259,026	D(2)
Common Stock	06/22/2021		P		277,777	A	$18	3,536,803	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	(1)	06/22/2021		C			10,000,000	(1)	(1)	Common Stock	2,933,583	(1)	0	D(2)
Series C Convertible Preferred Stock	(1)	06/22/2021		C			1,109,368	(1)	(1)	Common Stock	325,443	(1)	0	D(2)

1. Name and Address of Reporting Person^*

Droia Invest II SCSp

(Last) (First) (Middle)

28 BOULEVARD JOSEPH II

(Street)

LUXEMBOURG N4 L-1840

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Wepaven BV

(Last) (First) (Middle)

BRUSSELSESTEENWEG 11

(Street)

MEISE C9 1860

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

DF II GP Sarl

(Last) (First) (Middle)

28 BOULEVARD JOSEPH II

(Street)

LUXEMBOURG N4 L-1840

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

IHL SA

(Last) (First) (Middle)

28 BOULEVARD JOSEPH II

(Street)

LUXEMBOURG N4 L-1840

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Verelst Luc

(Last) (First) (Middle)

28 BOULEVARD JOSEPH II

(Street)

LUXEMBOURG N4 L-1840

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Naesens Janwillem

(Last) (First) (Middle)

128 SPRING ST, BUILDING A, SUITE 510

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

Explanation of Responses:

1. Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.

2. Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by Janwillem Naesens) and IHL SA (represented by Luc Verelst), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. Mr. Naesens, a member of the Issuer's board of directors, disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. Luc Verelst disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Remarks:

	Droia Invest II SCSp, By: DF II GP Sarl, By: /s/ Janwillem Naesens, Name: Wepaven BV (represented by Janwillem Naesens), Title: Manager	06/24/2021
	DF II GP Sarl, By: /s/ Janwillem Naesens, Name: Wepaven BV (represented by Janwillem Naesens), Title: Manager	06/24/2021
	Wepaven BV, By: /s/ Janwillem Naesens, Name: Janwillem Naesens, Title: Director	06/24/2021
	IHL SA, By: /s/ Luc Verelst, Name: Luc Verelst, Title: Director	06/24/2021
	Luc Verelst, By: /s/ Luc Verelst	06/24/2021
	Janwillem Naesens, By: /s/ Janwillem Naesens	06/24/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.